Fmr LLC Lowers Stake in MaxCyte, Inc. (NASDAQ:MXCT)

FMR LLC decreased its position in shares of MaxCyte, Inc. (NASDAQ:MXCT - Free Report) by 12.8% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 2,982,549 shares of the company's stock after selling 437,232 shares during the quarter. FMR LLC owned approximately 2.83% of MaxCyte worth $11,602,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD lifted its holdings in MaxCyte by 20.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 25,199 shares of the company's stock valued at $106,000 after purchasing an additional 4,320 shares during the last quarter. Chevy Chase Trust Holdings LLC lifted its stake in shares of MaxCyte by 2.0% during the 2nd quarter. Chevy Chase Trust Holdings LLC now owns 1,322,560 shares of the company's stock valued at $5,184,000 after buying an additional 26,163 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in MaxCyte by 24.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 423,209 shares of the company's stock worth $1,659,000 after buying an additional 83,025 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in MaxCyte by 22.1% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 32,735 shares of the company's stock valued at $128,000 after acquiring an additional 5,927 shares during the period. Finally, Rhumbline Advisers lifted its position in shares of MaxCyte by 15.3% during the second quarter. Rhumbline Advisers now owns 157,616 shares of the company's stock worth $618,000 after acquiring an additional 20,864 shares in the last quarter. Hedge funds and other institutional investors own 68.81% of the company's stock.

MaxCyte Trading Down 2.0 %

Shares of NASDAQ MXCT traded down $0.09 during mid-day trading on Thursday, hitting $4.34. The company had a trading volume of 353,305 shares, compared to its average volume of 536,336. MaxCyte, Inc. has a 1 year low of $3.16 and a 1 year high of $5.55. The company has a market capitalization of $458.70 million, a price-to-earnings ratio of -13.03 and a beta of 1.37. The stock's 50-day moving average price is $3.67 and its 200-day moving average price is $4.07.

MaxCyte (NASDAQ:MXCT - Get Free Report) last issued its earnings results on Wednesday, November 6th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.02. MaxCyte had a negative return on equity of 16.00% and a negative net margin of 78.36%. The business had revenue of $8.16 million during the quarter, compared to the consensus estimate of $7.50 million. During the same quarter last year, the company earned ($0.11) EPS. As a group, equities research analysts forecast that MaxCyte, Inc. will post -0.42 earnings per share for the current year.

Insider Activity at MaxCyte

In other MaxCyte news, Director Stanley C. Erck sold 21,607 shares of the firm's stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $3.71, for a total value of $80,161.97. Following the sale, the director now owns 269,118 shares of the company's stock, valued at $998,427.78. This trade represents a 7.43 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Over the last 90 days, insiders sold 27,607 shares of company stock valued at $102,782. Corporate insiders own 3.00% of the company's stock.

MaxCyte Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.